Press release
Oncolytic Virus Immunotherapy Market to Reach US$ 572.2 Million by 2031, Driven by Advances in Cancer Treatment and Biotech Innovations - Transparency Market Research Inc.
Oncolytic Virus Immunotherapy
The global oncolytic virus immunotherapy market was valued at US$ 110.2 million in 2022 and is expected to expand at a CAGR of 21.1% from 2023 to 2031, reaching US$ 572.2 million by the end of the forecast period. Key factors propelling market growth include advancements in viral vector technology, increasing clinical trials, and growing adoption of combination therapies with immune checkpoint inhibitors
Get Sample PDF Brochure from here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=44931
Analyst Viewpoint
Analysts anticipate robust growth in the oncolytic virus immunotherapy market due to increasing R&D activities, strategic collaborations among pharmaceutical companies, and the development of novel therapeutic candidates. However, challenges such as manufacturing complexities and stringent regulatory pathways may slow down market penetration.
Market Demand and Key Drivers
Rising Cancer Prevalence: The increasing global cancer burden is driving demand for innovative treatment modalities.
Advancements in Viral Engineering: Improved genetic modifications enhance virus targeting and effectiveness.
Growing Adoption of Combination Therapies: Synergistic effects with checkpoint inhibitors and chemotherapy boost treatment efficacy.
Favorable Regulatory Approvals: Accelerated approvals and orphan drug designations support market expansion.
Expanding Investment in Immuno-oncology: Increased funding for cancer research fosters new therapeutic developments.
Recent Developments
2022, Amgen: Expanded clinical trials for its oncolytic virus therapy, T-VEC, in combination with checkpoint inhibitors.
2023, Replimune Group: Announced positive Phase II results for its oncolytic virus-based melanoma treatment.
2023, Oncorus: Launched a new platform for intravenously administered oncolytic viral therapies.
2024, SillaJen: Partnered with major biotech firms to develop novel oncolytic virotherapies.
2024, Bristol-Myers Squibb: Acquired an emerging biotech company specializing in oncolytic virus platforms.
Key Market Players
Merck & Co., Inc. (Viralytics Limited)
Amgen Inc.
Shanghai Sunway Biotech Co., Ltd.
TILT Biotherapeutics
Oncorus, Inc.
Replimune Group, Inc.
Oncolys Biopharma, Inc.
Sorrento Therapeutics, Inc.
Oncolytics Biotech, Inc.
SillaJen, Inc.
Visit our report to discover essential insights and analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=44931
Market Trends and Opportunities
Increasing Interest in Personalized Oncolytic Therapies: Tailoring treatments based on tumor genetics.
Integration with Artificial Intelligence: AI-driven discovery for optimized viral design.
Expansion in Emerging Markets: Rising healthcare investments in Asia-Pacific and Latin America.
Development of Multi-Targeting Oncolytic Viruses: Enhancing efficacy through dual-action mechanisms.
Collaboration Between Pharma and Biotech Firms: Driving innovation and accelerated commercialization.
Market Segmentation
By Virus Type:
Herpes Simplex Virus (HSV)
Adenovirus
Reovirus
Newcastle Disease Virus (NDV)
Others
By Application:
Melanoma
Breast Cancer
Lung Cancer
Glioblastoma
Others
By End-User:
Hospitals
Cancer Research Centers
Biotech & Pharmaceutical Companies
Regional Analysis
North America: Strong regulatory support and high adoption of advanced therapies drive growth.
Europe: Increasing government funding and clinical trials boost market expansion.
Asia-Pacific: Growing prevalence of cancer and rising healthcare expenditures propel demand.
Latin America & Middle East/Africa: Improving access to innovative treatments supports market growth.
Future Market Analysis
The oncolytic virus immunotherapy market is poised for rapid expansion, fueled by advancements in virotherapy, increasing collaborations, and rising demand for alternative cancer treatments. The integration of AI in drug discovery, coupled with a focus on combination therapies, is expected to revolutionize the market landscape. Companies investing in next-generation viral immunotherapies will gain a competitive edge in this evolving industry.
Explore Latest Research Reports by Transparency Market Research:
Healthcare Biometrics Market: https://www.pharmiweb.com/press-release/2025-03-12/healthcare-biometrics-market-to-surpass-us-7408-billion-by-2035-driven-by-advancements-in-security-digital-health-solutions-tmr-insights
Healthcare Contract Research Outsourcing Market: https://www.pharmiweb.com/press-release/2025-03-12/healthcare-contract-research-outsourcing-market-to-surpass-us-6309-billion-by-2035-driven-by-increasing-demand-for-cost-effective-drug-development
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact Us:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Oncolytic Virus Immunotherapy Market to Reach US$ 572.2 Million by 2031, Driven by Advances in Cancer Treatment and Biotech Innovations - Transparency Market Research Inc. here
News-ID: 3939007 • Views: …
More Releases from Transparency Market Research
Global SiC Ceramics Market Poised for Robust Growth, Projected to Reach USD 3.1 …
The global silicon carbide (SiC) ceramics market continues to demonstrate strong growth potential, underpinned by accelerating demand from advanced industrial and electronic applications. Valued at US$ 1.8 Billion in 2024, the market is projected to reach US$ 3.1 Billion by 2035, expanding at a compound annual growth rate (CAGR) of 5.2% during the forecast period from 2025 to 2035. This steady expansion reflects the increasing importance of SiC ceramics as…
Furfuryl Alcohol Market to Reach USD 1.34 Billion by 2035, Supported by Rising D …
The global Furfuryl Alcohol Market was valued at US$ 624.3 million in 2024 and is projected to reach US$ 1,341.2 million by 2035, expanding at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2035.
This growth is primarily driven by the rising demand for bio-based and sustainable chemicals, along with the steady expansion of the foundry and metal casting industry, particularly across emerging economies in Asia Pacific.
Gain a…
Air-Entraining Agents Market Outlook 2035: Forecast to Reach US$ 2.48 Billion by …
The global Air-Entraining Agents (AEAs) Market was valued at US$ 1.70 billion in 2024 and is projected to reach US$ 2.48 billion by 2035, expanding at a compound annual growth rate (CAGR) of 3.5% from 2025 to 2035. This steady growth trajectory reflects the essential role AEAs play in modern concrete formulations, particularly in infrastructure projects that demand long-term durability, freeze-thaw resistance, and improved workability.
Despite being a mature segment within…
A2P SMS Market Outlook 2035: Expanding from US$ 71.2 Bn in 2024 to US$ 117.0 Bn …
The global Application-to-Person (A2P) SMS market is entering a phase of steady and resilient expansion, driven by the growing need for secure, reliable, and real-time communication between enterprises and consumers. Valued at US$ 71.2 Bn in 2024, the market is projected to reach US$ 117.0 Bn by 2035, expanding at a CAGR of 4.2% from 2025 to 2035. Despite the rise of internet-based messaging platforms, A2P SMS continues to maintain…
More Releases for Oncolytic
Prominent Oncolytic Virus Therapy Market Trend for 2025: Accelerating Oncolytic …
Which drivers are expected to have the greatest impact on the over the oncolytic virus therapy market's growth?
The rise in cancer incidences is likely to fuel the expansion of the oncolytic virus therapy market. Oncolytic virus therapy is gaining traction as an appealing approach to treating cancer- a collection of diseases marked by abnormal cell growth and proliferation. This therapeutic strategy effectively targets and eliminates cancer cells, while also triggering…
Enhancing the Immune Response with Oncolytic Virus Therapy
Oncolytic virus therapy is revolutionizing cancer treatment by harnessing the unique characteristics of viruses to specifically target and destroy cancer cells. This cutting-edge approach represents a significant advancement in cancer care, offering renewed hope for patients with different types of cancer.
Download Report:
https://www.kuickresearch.com/report-oncolytic-virus-immunotherapy-market-oncolytic-virus-therapy-market-oncolytic-virus-fda-approved-oncolytic-virus-clinical-trilas
The essence of oncolytic virus therapy is based on genetically modified viruses that can selectively attack and kill cancer cells while leaving healthy tissue unharmed. These engineered viruses take…
Creative Biolabs Unleashes Solutions to Validate Oncolytic Virotherapy
Creative Biolabs introduces safety and efficacy validation strategies for oncolytic virotherapy.
New York, USA - June 17, 2024 - Oncolytic virotherapy appears as a new paradigm in cancer immunotherapy that enrolls specifically engineered viruses to selectively infect and kill cancer cells, some of which have marched into clinical trials, like adenoviruses, HSV, reovirus, vaccinia virus, and measles. With so many other candidates still on their preclinical journey, the requests to validate…
Oncolytic Virus Competitive Landscape 2023 (Updated)
DelveInsight's, "Oncolytic Virus Competitive Landscape 2023" report provides comprehensive insights about 150+ Oncolytic Virus Companies and 175+ drugs in the Oncolytic Virus Competitive landscape. It covers the Oncolytic Virus therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Oncolytic Virus Competitive Landscape Report
• DelveInsight's Oncolytic Virus report depicts a robust space with 150+ Oncolytic…
Oncolytic Virus Therapy Market Oncolytic Virus Therapy Clinical Pipeline Report …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Prologue to Oncolytic Virus
1.1 Outline of Oncolytic Virotherapy
1.2 Trail from Genesis to Biogenetics
Primer of Virotherapy in Malignancies
2.1 Oncolytic Viruses towards Cancer
2.2 Approaches for Targeting Tumor Cells
2.2.1 Pro Apoptotic Targeting
2.2.2 Translational Targeting
2.2.3 Transcriptional Targeting
2.2.4 Transductional Targeting
Mechanism…
Global Oncolytic Virus Therapy Report Highlight Market Opportunity & Insight On …
“Global Oncolytic Virus Therapy Market and Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic…
